Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336603 | 0.88 | MEN1 (0.47) | MEN1PABPC1KMT2ACA12CA1 | |
| Water SCHEMBL10648619 | 0.86 | MEN1 (0.46) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL22847416 | 0.86 | MEN1 (0.47) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL14980053 | 0.86 | MEN1 (0.47) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13028034 | 0.83 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL25434536 | 0.81 | MEN1 (0.43) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL7876576 | 0.81 | MEN1 (0.69) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL26321485 | 0.81 | MEN1 (0.42) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL14980051 | 0.81 | MEN1 (0.42) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL13027731 | 0.74 | MEN1 (0.71) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025034537-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | PKD1, APC, VHL | MEN1 1199/4885PABPC1 4026/4885KMT2A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.